Novartis and Schering-Plough restructure global respiratory deal
This article was originally published in Scrip
Executive Summary
Novartis and Schering-Plough are restructuring their global development and commercialisation collaboration for fixed-dose combination therapies for asthma and chronic obstructive pulmonary disease.